Skip to main content
Category

News Archive

tasso-logo

DARPA Sponsors New Self-Administered Pain-Free Blood Testing Tech

By News Archive

tasso-logo

Blood draws typically require trained professionals to perform and can be both frightening and painful to patients. Tasso, Inc., a spinoff of the Unviersity of Wisconsin-Madison, has developed a device that can be applied by the patients themselves to nearly painlessly draw blood.

The device works thanks to capillary action, slowly pulling in blood through a tiny channel over a two minute period. Once the process is complete, the patient simply takes the device to a clinical lab for testing. Since current methods require refrigeration of blood samples during shipment, DARPA is giving Tasso $3 million to work with other firms to develop a way to extend to a week the time the blood samples can be safely stored at up to 140° F (60° C).

Read More
1776-incubator-logo

Can tech incubator 1776 cook up its own business? – The Washington Post

By News Archive

1776-incubator-logo

The tech incubator 1776 is a collegial place, with offices painted in lively colors, couches to greet visitors, and members who share seats, desks and the fixings for peanut butter and jelly sandwiches.

It’s an atmosphere carefully cultivated by its founders, Evan Burfield and Donna Harris, and it helped position the outfit as a caretaker, connector and capital provider for tomorrow’s big technology companies.

Read More
himss-logo

At HIMSS, DeSalvo, Slavitt stay optimistic about health IT’s future

By News Archive

himss-logo

In the face of growing criticism and impatience with the Meaningful Use EHR incentive program, National Health IT Coordinator Dr. Karen DeSalvo remains upbeat but aware of the tough work ahead to achieve the vision of a learning health system underpinned by a network of interoperable EHRs.

“Interoperability is a priority, but it is still just a means to an end,” De Salvo said Thursday morning in a keynote session on the last day of HIMSS15 at McCormick Place in Chicago. Without interoperability, it will be difficult to achieve healthcare payment and delivery reform, she added.

Read More
wsahington-dc-ariel-lincoln-pixa

Washington’s venture capital machine churning out fewer but much larger deals – The Washington Post

By News Archive

wsahington-dc-ariel-lincoln-pixa

Washington companies raised more venture capital funding in the first quarter than they have during the first three months of any year in more than a decade, building on momentum the industry mustered up late last year.

During the first quarter, 38 Washington companies hauled in roughly $329.9 million from venture capitalists, a 55 percent increase over the $212.5 million raised by firms in the region during the same period last year, according to the latest round of data from PricewaterhouseCoopers and the National Venture Capital Association. While that’s down slightly from a surge last quarter, in which investors poured $363.5 million into local companies, it’s well above last year’s sluggish quarterly average ($270.4 million) and the largest first-quarter haul since 2001.

Read More
bwtech logo

Northrop Grumman and bwtech@UMBC Graduate Fifth Cyber Startup from Cync Incubator Program NYSE:NOC

By News Archive

bwtech-logo

Northrop Grumman Corporation (NYSE:NOC) and the bwtech@UMBC Cyber Incubator announced today that continuous monitoring solutions provider DB Networks® will be the fifth cyber startup to graduate from the highly successful Cync Program. A ceremony marking the occasion is scheduled for next week during the RSA Conference 2015 in San Francisco, California.

OptioLabs of Baltimore joins Cync this month as the newest cyber startup accepted into the program since it began in 2011.

Read More
1776-incubator-logo

What is 1776 trying to become? – Washington Business Journal

By News Archive

1776-incubator-logo

The news broke just after midnight Thursday that D.C. tech accelerator 1776 would acquire Disruption Corp. — both its Crystal Tech Fund, which currently includes 12 portfolio companies, and the startup-focused, data-crunching software that formed the foundation of Paul Singh’s Crystal City enterprise.

It can’t be denied that 1776 has built a rather explosive brand since it first popped on the scene in 2013. President Barack Obama and United Kingdom Prime Minister David Cameron have toured the premises. Partnerships have been forged with several monster corporations (like Comcast and Microsoft) and, as of this week, two local municipalities (Montgomery and Arlington). Legions of startups work out of the District offices. And Virginia Gov. Terry McAuliffe will be speaking at Thursday’s formal announcement of the deal.

Read More
dreamit-health-baltimore-logo

CEO’s Note: Dreaming It in Charm City — Sisu Global Health

By News Archive

dreamit-health-baltimore-logo

The field of blood study and blood-related product development is a small one, and the field of autotransfusion (blood recycling) is even smaller. It often seems like everyone knows everyone else. We’ve had a lot of great mentors in the blood space from afar, but it hasn’t been until we tapped into the inner workings of the Baltimore/DC area that we realized quite how small.

Just six weeks ago, we moved to the Charm City for the DreamIt Health Accelerator program from our medical device manufacturing home in Grand Rapids, Michigan. We were looking for other resources and mentors in both the blood transfusion and global health community to take our company to the next level, and we’ve found them.

Read More
medimmune-logo

Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma

By News Archive

medimmune-logo

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a collaboration to conduct clinical trials in immuno-oncology with Immunocore Limited, a privately-held UK-based biotechnology company.

Under the terms of the agreement, Immunocore will conduct a Phase Ib/II clinical trial combining MedImmune’s investigational checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100, Immunocore’s lead T-cell receptor-based investigational therapeutic, for the potential treatment of patients with metastatic melanoma.  MedImmune has an exclusive relationship with Immunocore for the development of IMCgp100 in combination with MEDI4736 and/or tremelimumab, and will have first right of negotiation for the future commercial development of these combinations for tumours expressing glycoprotein 100 (gp100), a tumour-associated antigen.

Read More
baltimore-inner-harbor-pixa

Baltimore’s tech talent growth outpaces most other cities – Baltimore Business Journal

By News Archive

baltimore-inner-harbor-pixa

Baltimore may not have the startup mecca reputation of Silicon Valley or Boston, but it is one of the fastest growing tech talent markets.

The city’s tech talent pool grew by 42 percent between 2010 and 2013, making Baltimore one of the fastest growing tech talent markets in the country, according to a new report by CBRE, a commercial real estate brokerage. Only San Francisco and the San Francisco Peninsula reported a faster growth rate than Baltimore. Tech talent grew 44 percent in those areas.

Read More
nea-logo

How much of NEA’s new, $3.1 billion fund will finance healthcare companies? A third, perhaps.

By News Archive

nea-logo

Venture firm New Enterprise Associates made some massive waves today on news that it’s closed its fifteenth – and largest – fund, which holds $3.1 billion. And a huge swath of that – 30 to 40 percent, according to Fierce – could likely be allocated to the healthcare space.

MedCity News reported initially on NEA’s plans to raise funds – it filed a document with the SEC in January indicating a $2.5 billion fundraise:

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.